Karen Carey

Advancis Restructures, Cuts Staffs Following Ended Deal

Nov. 22, 2004

Emisphere Signs Roche To Deal For Eligen Technology

Nov. 19, 2004

In its first license agreement for small-molecule compounds, Emisphere Technologies Inc. signed on with F. Hoffmann-La Roche Ltd. to develop oral formulations of approved therapies for bone-related diseases. (BioWorld Today)

Stressgen's HspE7 Positive In Cervical Dysplasia Study

Nov. 18, 2004

By Karen Carey

Demonstrating a 40 percent response rate in high-grade cervical dysplasia patients, Stressgen Biotechnologies Corp.'s lead candidate, HspE7, appears to be heading toward another Phase III trial. (BioWorld Today)

Chiron Backs Away From BLA Filing For Menjugate Vaccine

Nov. 16, 2004

By Karen Carey

Reata's Series C Gets $12M To Progress Cancer Drugs

Nov. 15, 2004

By Karen Carey

Geron Raises $40M Privately To Fund Oncology Products

Nov. 12, 2004

By Karen Carey

CST's Technology Discovering Biomarkers For Kinase Targets

Nov. 11, 2004

By Karen Carey

Aventis Drops Genasense Deal On Phase III CLL Data

Nov. 10, 2004

By Karen Carey

Losing half of its value, Genta Inc.'s stock slid south on Tuesday following news that Genasense did not meet key secondary endpoints and had safety issues in a Phase III trial, causing Aventis to drop out as a marketing partner. (BioWorld Today)